Better Health for All

Quoin Pharmaceuticals' core product, QRX003, is a topical lotion for Netherton Syndrome, a rare, severe, and potentially fatal genetic skin disease with no approved treatment.

Clinical data consistently shows significant positive health benefits, including rapid and almost complete skin healing, elimination of key symptoms like pruritus, resolution of sleep disturbances, and the ability for patients to discontinue other medications. Multiple clinical studies for QRX003 have reported no adverse reactions or events. The company's innovation is focused on developing this topical lotion with proprietary delivery technology to address the root cause of the disease. The FDA has granted QRX003 Rare Pediatric Disease Designation. Clinical trials are conducted under FDA-approved IND applications and are randomized, double-blinded, and vehicle-controlled. The company has established a patient-specific website to facilitate awareness and participation in clinical studies. There is no information regarding the company's approach to patents or intellectual property.

Fair Money & Economic Opportunity

Quoin Pharmaceuticals, Ltd. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases.

The company's core business activities involve research and development, clinical trials, and seeking regulatory approvals for pharmaceutical products. It does not engage in lending, insuring, moving, or storing money, nor does it offer consumer financial products or services. Therefore, all Key Performance Indicators under the 'Fair Money & Economic Opportunity' value are not applicable to its operations, as this value specifically evaluates financial institutions and their services.

Fair Trade & Ethical Sourcing

Quoin Pharmaceuticals, Ltd. does not manufacture or distribute its products directly, focusing instead on development and commercialization. This business model means the company does not engage in the direct procurement of physical commodities or raw materials that would typically be subject to fair trade certifications, supply chain audits, or have exposure to upstream labor practices.

Consequently, all KPIs related to fair trade and ethical sourcing are scored as N/A due to the absence of a relevant supply chain for physical goods.

Honest & Fair Business

Quoin Pharmaceuticals received a deficiency letter from Nasdaq on April 29, 2024, due to its ADS price falling below $1.00 for 31 consecutive business days, with an extension granted until April 28, 2025, to regain compliance.

The company adopted a Code of Ethics and Business Conduct on March 14, 2023, which applies to all directors, officers, and employees. This code includes a non-retaliation clause for good-faith reporting and provides a secure web portal and phone number to the Audit Committee Chairman for reporting complaints. Over the past five years, the company has undergone three reverse stock splits: 1-for-12.5 on August 1, 2022; 1-for-12 on July 18, 2023; and 1-for-60,000 on November 8, 2023. The company's audit committee charter specifies that the Chairman of the Board, directors employed by a controlling shareholder, or directors whose main income depends on a controlling shareholder, as well as controlling shareholders or their relatives, are prohibited from being members of the audit committee. The Code of Ethics and Business Conduct states a commitment to never offering or accepting bribes, kickbacks, or other improper payments, directly or indirectly, and includes an Insider Trading Policy.

Planet-Friendly Business

Sustainability data for QNRX.US is currently unavailable, with a complete absence of quantitative data across most environmental metrics.

However, the company has no recorded regulatory actions, violations, fines, or compliance issues.

Respect for Cultures & Communities

The provided articles focus on Quoin Pharmaceuticals' clinical trials, regulatory designations for its product QRX003, corporate governance, and international expansion of clinical trial sites, including one new site in Saudi Arabia.

No information is available regarding the company's engagement with local or indigenous communities, cultural impact assessments, community investment, local employment, grievance mechanisms, or any other metrics related to respect for cultures and communities.

Safe & Smart Tech

The company's privacy policy, updated in September 2021, states that data is collected only as necessary.

It specifies retention periods for comments (one year) and various cookies (ranging from one day to one year). Users can request deletion of personal data and opt-out of promotional emails. The company also states its compliance with applicable laws, including those outside the user's country of residence.